NYSE · CNMD

CONMED Corporation

$43.51 +$0.83 (+1.94%) 1D Pre-market
Session Pulse Pre-market 1 mentions on Fri · 1 bullish / 0 bearish tags No new SEC filings since Mon close its sector ranked 5/11 this week Full pulse →

Key Metrics

$1.29B
Market cap
27.31×
P/E · TTM
$1.37B
Revenue · TTM
$47.06M
Net income
EPS · TTM $1.49
Dividend yield 1.9%
Free cash flow $150.88M
Beta · 1Y 0.86
EBITDA · TTM $88.26M
Gross margin 54.6%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 13
    The stock moved +10.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 13
  • Jul 9
    The stock moved +9.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 9
  • Jun 17
    From its Feb 24 high, the share price fell 30%.

    Peak close $46.06 on Feb 24; trough close $32.11 on Jun 17. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -30%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.29B
Enterprise value
Shares outstanding30.1M
52-wk range$31.44 – $56.64
Avg volume · 20D402.0K
Net cash
Book value / share$32.75
IndustryElectromedical & Electrotherapeutic Apparatus
ExchangeNYSE
About CONMED Corporation
IPO dateJul 23, 1987
Employees3900

Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E27.31
P/S0.93
P/FCF8.52
EV/EBITDA
EV/Sales
Graham №$33.15

Profitability

Gross 54.6%
Operating 5.2%
Net 3.4%
FCF 11.0%
ROE / ROIC 4.7% · —

Financial Health

Current ratio2.14
Quick ratio1.01
Debt / equity0.81
Debt / EBITDA 9.46
Net cash
Working capital$357.82M

Cash Flow · TTM

Operating CF $170.69M
Capex −$19.81M
Free cash flow $150.88M
Buybacks
Dividends paid $24.75M
Shareholder yield 1.9%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

1.8
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$33.15 vs $43.51
Trades 1.3× above classic defensive value — priced for growth
Fundamentals through 2025-09-30 · computed by TickerWolf from SEC filings